BARICITINIB (Olumiant) Nursing Considerations

What is the generic name?

BARICITINIB

What is the Trade Name for BARICITINIB?

Olumiant

What are the Indications for BARICITINIB?

• 1 INDICATIONS AND USAGE OLUMIANT ¬Æ is a Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitation of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) 1.1 Rheumatoid Arthritis OLUMIANT ¬Æ (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. Limitation of Use : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

References: https://open.fda.gov/